RNXT Quote, Financials, Valuation and Earnings

DocGo, Inc. has a net margin of -1094.74% compared to RenovoRx, Inc.'s net margin of -41.88%. RenovoRx, Inc.'s return on equity of -127.86% beat DocGo, Inc.'s return on equity of -20.69%.

RenovoRx, Inc. has a consensus price target of $5.56, signalling upside risk potential of 582.68%. On the other hand DocGo, Inc. has an analysts' consensus of $2.75 which suggests that it could grow by 210.24%. Given that RenovoRx, Inc. has higher upside potential than DocGo, Inc., analysts believe RenovoRx, Inc. is more attractive than DocGo, Inc..

RenovoRx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DocGo, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

RenovoRx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DocGo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RenovoRx, Inc. pays -- of its earnings as a dividend. DocGo, Inc. pays out -- of its earnings as a dividend.

RenovoRx, Inc. quarterly revenues are $266K, which are smaller than DocGo, Inc. quarterly revenues of $70.8M. RenovoRx, Inc.'s net income of -$2.9M is higher than DocGo, Inc.'s net income of -$29.7M. Notably, RenovoRx, Inc.'s price-to-earnings ratio is -- while DocGo, Inc.'s PE ratio is 8.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RenovoRx, Inc. is 28.24x versus 0.24x for DocGo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Dyadic International, Inc. has a net margin of -1094.74% compared to RenovoRx, Inc.'s net margin of -169.67%. RenovoRx, Inc.'s return on equity of -127.86% beat Dyadic International, Inc.'s return on equity of -413.59%.

RenovoRx, Inc. has a consensus price target of $5.56, signalling upside risk potential of 582.68%. On the other hand Dyadic International, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 686.61%. Given that Dyadic International, Inc. has higher upside potential than RenovoRx, Inc., analysts believe Dyadic International, Inc. is more attractive than RenovoRx, Inc..

RenovoRx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Dyadic International, Inc. has a beta of 1.236, suggesting its more volatile than the S&P 500 by 23.569%.

RenovoRx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dyadic International, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RenovoRx, Inc. pays -- of its earnings as a dividend. Dyadic International, Inc. pays out -- of its earnings as a dividend.

RenovoRx, Inc. quarterly revenues are $266K, which are smaller than Dyadic International, Inc. quarterly revenues of $1.2M. RenovoRx, Inc.'s net income of -$2.9M is lower than Dyadic International, Inc.'s net income of -$2M. Notably, RenovoRx, Inc.'s price-to-earnings ratio is -- while Dyadic International, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RenovoRx, Inc. is 28.24x versus 8.28x for Dyadic International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

GT Biopharma, Inc. has a net margin of -1094.74% compared to RenovoRx, Inc.'s net margin of --. RenovoRx, Inc.'s return on equity of -127.86% beat GT Biopharma, Inc.'s return on equity of -626.24%.

RenovoRx, Inc. has a consensus price target of $5.56, signalling upside risk potential of 582.68%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 769.47%. Given that GT Biopharma, Inc. has higher upside potential than RenovoRx, Inc., analysts believe GT Biopharma, Inc. is more attractive than RenovoRx, Inc..

RenovoRx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.

RenovoRx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RenovoRx, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.

RenovoRx, Inc. quarterly revenues are $266K, which are larger than GT Biopharma, Inc. quarterly revenues of --. RenovoRx, Inc.'s net income of -$2.9M is higher than GT Biopharma, Inc.'s net income of -$3.1M. Notably, RenovoRx, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RenovoRx, Inc. is 28.24x versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Scienture Holdings, Inc. has a net margin of -1094.74% compared to RenovoRx, Inc.'s net margin of -611.42%. RenovoRx, Inc.'s return on equity of -127.86% beat Scienture Holdings, Inc.'s return on equity of -24.88%.

RenovoRx, Inc. has a consensus price target of $5.56, signalling upside risk potential of 582.68%. On the other hand Scienture Holdings, Inc. has an analysts' consensus of -- which suggests that it could grow by 1219.91%. Given that Scienture Holdings, Inc. has higher upside potential than RenovoRx, Inc., analysts believe Scienture Holdings, Inc. is more attractive than RenovoRx, Inc..

RenovoRx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Scienture Holdings, Inc. has a beta of 2.959, suggesting its more volatile than the S&P 500 by 195.932%.

RenovoRx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Scienture Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $1.50 per share. RenovoRx, Inc. pays -- of its earnings as a dividend. Scienture Holdings, Inc. pays out 81.44% of its earnings as a dividend. Scienture Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

RenovoRx, Inc. quarterly revenues are $266K, which are smaller than Scienture Holdings, Inc. quarterly revenues of $590K. RenovoRx, Inc.'s net income of -$2.9M is higher than Scienture Holdings, Inc.'s net income of -$3.6M. Notably, RenovoRx, Inc.'s price-to-earnings ratio is -- while Scienture Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RenovoRx, Inc. is 28.24x versus 10.03x for Scienture Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.